Relevant bibliographies by topics / Recombinant interferon

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Recombinant interferon'

Author: Grafiati
Published: 7 June 2025
Last updated: 17 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Recombinant interferon.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Recombinant interferon"

1

Yaar, M., A. V. Palleroni, and B. A. Gilchrest. "Normal human epidermis contains an interferon-like protein." Journal of Cell Biology 103, no. 4 (1986): 1349–54. http://dx.doi.org/10.1083/jcb.103.4.1349.

Full text
Abstract:
Interferons have been postulated to participate in growth regulation of normal body tissues and are known to inhibit growth of human epidermal keratinocytes in vitro. Polyclonal antibodies to recombinant human interferon-alpha, purified by passage over an affinity column (Sepharose coupled to the recombinant interferon), used in the indirect immunofluorescent method specifically stained the proliferative (basal) compartment of human epidermis in histological cross-sections of normal skin and in cultured keratinocyte colonies. Extracts prepared from healthy nonvirally infected keratinocyte cultures contained interferon activity as determined by viral plaque inhibition assay. Using the Western blotting technique column-purified antibodies and antisera to recombinant human interferon-alpha recognized a band of approximately 40 kD when reacted with both extracted keratinocyte proteins and recombinant human interferon-alpha standards, that gave in addition a band of approximately 20 kD. The above findings suggest that interferon or a closely related protein is present in the proliferative compartment of normal epidermis in the absence of viral infection and therefore may serve as a physiological modulator of epidermal growth.
APA, Harvard, Vancouver, ISO, and other styles
2

Wagstaff, Antona J., and Karen L. Goa. "Recombinant Interferon-??-1a*." BioDrugs 10, no. 6 (1998): 471–94. http://dx.doi.org/10.2165/00063030-199810060-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Weinberg, JM, JT Wolfe, S. Sood, M. Saruk, AH Rook, and EM Spiers. "Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature." Acta Dermato-Venereologica 77, no. 2 (1997): 146–48. http://dx.doi.org/10.2340/00015555577146148.

Full text
Abstract:
Interferons are cytokines produced by cells in response to stimulation by certain antigens and infectious agents. In recent years, recombinant interferons have been developed, which have antiviral, antiproliferative, and immunomodulatory functions. Several cutaneous reactions have been reported, including cutaneous ulceration at injection sites. We now report three cases of cutaneous ulceration caused by interferon beta-1b injections. In addition, we review all of the previously reported cases of cutaneous ulceration caused by recombinant interferons and discuss the different mechanisms by which these substances may produce this effect.
APA, Harvard, Vancouver, ISO, and other styles
4

Kurzrock, R., M. G. Rosenblum, J. R. Quesada, S. A. Sherwin, L. M. Itri, and J. U. Gutterman. "Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients." Journal of Clinical Oncology 4, no. 11 (1986): 1677–83. http://dx.doi.org/10.1200/jco.1986.4.11.1677.

Full text
Abstract:
Combinations of interferon-alpha and interferon-gamma demonstrate synergistic antiviral and anti-proliferative activity in vitro. Therefore, we initiated a clinical study of combination interferon therapy in humans. Eighteen patients with metastatic solid tumors received daily intramuscular (IM) injections of recombinant interferon-alpha-A (IFN alfa-2a, Roferon-A; Hoffman-LaRoche, Nutley, NJ) and recombinant IFN-gamma (rIFN-gamma) for 6 weeks. The dose levels were 0.5, 1.0, 2.0, and 5.0 X 10(6) U/m2/d of each interferon. A minimum of two patients were entered sequentially at each dose level. Fever, chills, fatigue, and a greater than or equal to 50% drop in granulocyte counts were observed at all doses. Severity of symptoms corresponded to increasing dose levels. In contrast to the tachyphylaxis to these symptoms that usually develops in patients treated with the individual interferons, many patients on this study experienced persistent fever and worsening fatigue over 6 weeks. The maximum tolerated dose was 1 X 10(6) U/m2/d of each interferon. One patient with renal-cell carcinoma achieved a partial remission (duration, 3 months). Enzyme-linked immunoassay analysis in all four patients for whom complete data were available revealed that peak blood levels of IFN alfa-2a on day 22 were about tenfold higher than on day 1. Because of the possibility of cumulative toxicity, the recommended starting dose for further studies is 0.5 X 10(6) U/m2/d of each interferon, with escalation to 1.0 X 10(6) U/m2/d after 1 month if tolerance is acceptable. Phase II investigations to explore the antitumor efficacy of this regimen are planned.
APA, Harvard, Vancouver, ISO, and other styles
5

Tsygankov, Mikhail A., and Marina V. Padkina. "Influence of PDI gene overexpression on heterological proteins production in yeast Pichia pastoris." Ecological genetics 15, no. 2 (2017): 21–30. http://dx.doi.org/10.17816/ecogen15221-30.

Full text
Abstract:
Background. The yeast Pichia pastoris is used for synthesis of recombinant secretory proteins. Overexpression of assistant genes, coding proteins involved in secretion, is one of approaches to improve the production of target protein. PpPDI gene encodes P. pastoris yeast protein disulfide isomerase (Pdi). The aim of our study was to evaluate the effect of Pdi overproduction on recombinant interferons (human interferon-alfa16 and chicken interferon-gamma) production. Materials and Methods. PpPDI gene was cloned under the control of the AOX1 gene promoter in plasmid pPICZαA. Primers for AJ302014.1 nucleotide sequence of NCBI data base were used for PpPDI gene cloning. The chromosomal DNA of the GS115 strain was used as a template. To generate strains with PpPDI gene overexpression we used a previously obtained strains producing human interferon-alfa16 and chicken interferon-gamma. Yeast transformation was performed by electroporation. Cultivation was performed using single and two-stage strategies in standard media containing methanol as the sole carbon source to induce the AOX1 gene promoter. Results. We obtained interferon-producing strains with PpPDI gene overexpression. Over-expression of the PpPDI gene in yeast P. pastoris increases the production of interferon-alfa16, a protein containing disulfide bonds, regardless of the mode of cultivation. Effect of PpPDI gene over-expression on the production of interferon-gamma - the protein without disulfide bonds, depends on cultivation mode. Conclusion. PpPDI gene overexpression can be used to enhance the production of interferons and other proteins that contain disulfide bonds. Effect of PpPDI gene overexpression on recombinant proteins without disulfide bonds may depend on cultivation procedure.
APA, Harvard, Vancouver, ISO, and other styles
6

Pelus, L. M., O. G. Ottmann, and K. H. Nocka. "Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, -beta, and -gamma and an effect mediated by tumor necrosis factor." Journal of Immunology 140, no. 2 (1988): 479–84. http://dx.doi.org/10.4049/jimmunol.140.2.479.

Full text
Abstract:
Abstract The effects of prostaglandin E (PGE) and recombinant human interferon-alpha, -beta, and -gamma alone and in combination were tested for their effects on the proliferation of human bone marrow granulocyte-macrophage colony-forming units (GM-CFU). When tested alone, both classes of cytokines inhibited GM-CFU proliferation. In combination, PGE and all three types of recombinant interferons synergized in their ability to inhibit GM-CFU proliferation. Progressive enrichment for marrow GM-CFU indicated that the synergistic effects of PGE and interferon were dependent upon the presence of marrow-adherent cells. Studies using conditioned media from marrow-adherent cells prepared in the presence of interferon-alpha, -beta, and -gamma indicated that adherent cells produced a soluble factor in the presence of interferons that subsequently synergized with PGE in inhibiting GM-CFU proliferation. Neutralization of this conditioned media with a monoclonal antibody to tumor necrosis factor abrogated the synergistic inhibition of GM-CFU observed in the presence of PGE. The addition of recombinant tumor necrosis factor and PGE to accessory cell-depleted bone marrow resulted in synergystic inhibition of GM-CFU proliferation.
APA, Harvard, Vancouver, ISO, and other styles
7

Miller, BA, SP Perrine, G. Antognetti, et al. "Gamma-interferon alters globin gene expression in neonatal and adult erythroid cells." Blood 69, no. 6 (1987): 1674–81. http://dx.doi.org/10.1182/blood.v69.6.1674.1674.

Full text
Abstract:
Abstract Interferons have the ability to enhance or diminish the expression of specific genes and have been shown to affect the proliferation of certain cells. Here, the effect of gamma-interferon on fetal hemoglobin synthesis by purified cord blood, fetal liver, and adult bone marrow erythroid progenitors was studied with a radioligand assay to measure hemoglobin production by BFU-E-derived erythroblasts. Coculture with recombinant gamma-interferon resulted in a significant and dose- dependent decrease in fetal hemoglobin production by neonatal and adult, but not fetal, BFU-E-derived erythroblasts. Accumulation of fetal hemoglobin by cord blood BFU-E-derived erythroblasts decreased up to 38.1% of control cultures (erythropoietin only). Synthesis of both G gamma/A gamma globin was decreased, since the G gamma/A gamma ratio was unchanged. Picograms fetal hemoglobin per cell was decreased by gamma- interferon addition, but picograms total hemoglobin was unchanged, demonstrating that a reciprocal increase in beta-globin production occurred in cultures treated with gamma-interferon. No toxic effect of gamma-interferon on colony growth was noted. The addition of gamma- interferon to cultures resulted in a decrease in the percentage of HbF produced by adult BFU-E-derived cells to 45.6% of control. Fetal hemoglobin production by cord blood, fetal liver, and adult bone marrow erythroid progenitors, was not significantly affected by the addition of recombinant GM-CSF, recombinant interleukin 1 (IL-1), recombinant IL- 2, or recombinant alpha-interferon. Although fetal progenitor cells appear unable to alter their fetal hemoglobin program in response to any of the growth factors added here, the interaction of neonatal and adult erythroid progenitors with gamma-interferon results in an altered expression of globin genes. This supports the concept that developmental globin gene switching can be regulated by environmental factors.
APA, Harvard, Vancouver, ISO, and other styles
8

Miller, BA, SP Perrine, G. Antognetti, et al. "Gamma-interferon alters globin gene expression in neonatal and adult erythroid cells." Blood 69, no. 6 (1987): 1674–81. http://dx.doi.org/10.1182/blood.v69.6.1674.bloodjournal6961674.

Full text
Abstract:
Interferons have the ability to enhance or diminish the expression of specific genes and have been shown to affect the proliferation of certain cells. Here, the effect of gamma-interferon on fetal hemoglobin synthesis by purified cord blood, fetal liver, and adult bone marrow erythroid progenitors was studied with a radioligand assay to measure hemoglobin production by BFU-E-derived erythroblasts. Coculture with recombinant gamma-interferon resulted in a significant and dose- dependent decrease in fetal hemoglobin production by neonatal and adult, but not fetal, BFU-E-derived erythroblasts. Accumulation of fetal hemoglobin by cord blood BFU-E-derived erythroblasts decreased up to 38.1% of control cultures (erythropoietin only). Synthesis of both G gamma/A gamma globin was decreased, since the G gamma/A gamma ratio was unchanged. Picograms fetal hemoglobin per cell was decreased by gamma- interferon addition, but picograms total hemoglobin was unchanged, demonstrating that a reciprocal increase in beta-globin production occurred in cultures treated with gamma-interferon. No toxic effect of gamma-interferon on colony growth was noted. The addition of gamma- interferon to cultures resulted in a decrease in the percentage of HbF produced by adult BFU-E-derived cells to 45.6% of control. Fetal hemoglobin production by cord blood, fetal liver, and adult bone marrow erythroid progenitors, was not significantly affected by the addition of recombinant GM-CSF, recombinant interleukin 1 (IL-1), recombinant IL- 2, or recombinant alpha-interferon. Although fetal progenitor cells appear unable to alter their fetal hemoglobin program in response to any of the growth factors added here, the interaction of neonatal and adult erythroid progenitors with gamma-interferon results in an altered expression of globin genes. This supports the concept that developmental globin gene switching can be regulated by environmental factors.
APA, Harvard, Vancouver, ISO, and other styles
9

Lokshina, E. E., V. V. Malinovskaya, O. V. Zaytseva, and S. U. Snitko. "Virus-induced asthma: how to achieve good disease control?" Voprosy praktičeskoj pediatrii 15, no. 6 (2020): 52–66. http://dx.doi.org/10.20953/1817-7646-2020-6-52-66.

Full text
Abstract:
This article discusses the role of various respiratory viruses in the development of bronchial asthma and in triggering its exacerbation. It covers the pathogenetic mechanisms underlying virus-induced bronchial asthma and the importance of interferons for disease control. We summarized the results of international and Russian studies analyzing the utility of type 1 interferons for children and adults with virus-induced asthma exacerbations. Combination drugs containing recombinant α2b interferon plus α-tocopheryl acetate plus ascorbic acid have demonstrated their efficacy in the prevention and treatment of virus-induced asthma exacerbations in routine clinical practice. Moreover, these drugs were safe and well tolerated by patients, which opens new prospects for patients with virus-induced asthma. Key words: virus-induced bronchial asthma, respiratory viruses, children, interferons, therapy, recombinant α2b-interferon + α-tocopheryl acetate + ascorbic acid
APA, Harvard, Vancouver, ISO, and other styles
10

Hamilton, A. O., L. Jones, L. Morrison, and K. Whaley. "Modulation of monocyte complement synthesis by interferons." Biochemical Journal 242, no. 3 (1987): 809–15. http://dx.doi.org/10.1042/bj2420809.

Full text
Abstract:
Recombinant Escherichia coli-derived gamma-interferon has been shown to stimulate synthesis of the second component of complement (C2), factor B and C1 inhibitor, but to inhibit synthesis of the third component (C3). alpha- and beta-interferons stimulate synthesis of factor B and C3 inhibitor, inhibit C5 synthesis but do not alter synthesis of C2. alpha- and beta-interferons act synergistically with gamma-interferon to enhance both factor B and C1-inhibitor synthesis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Recombinant interferon"

1

Dias, Paulo Victor Sarmento. "Desenvolvimento de processo de produção e caracterização de interferon-α2a secretado no espaço periplásmico de Escherichia Coli." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-04122017-150200/.

Full text
Abstract:
Os IFN-&alpha;2 são atualmente utilizados em terapia de hepatite B e C, leucemia, mieloma múltiplo, leucemia de células pilosas, melanoma, sarcoma de Kaposi, linfoma folicular e carcinoma de células renais, em associação ou não com outras drogas. Este trabalho descreve um processo de produção, purificação e caracterização de interferon-&alpha;2a secretado para o espaço periplasmico de E. coli utilizando um vetor baseado no uso constitutivo do promotor lambda PL. Foi validada também uma análise em cromatografia líquida de alta eficiência em fase reversa (RP-HPLC) para monitoração do processo. Dessa forma, este trabalho descreve inicialmente um método de RP-HPLC para análise qualitativa e quantitativa de interferon-&alpha;2a e interferon-&alpha;2b. O método foi desenvolvido e validado quanto à recuperação, precisão, linearidade, sensibilidade e especificidade. O teste de recuperação indicou erro menor que 1 % e as determinações quantitativas intra-dia e inter-dia apresentaram desvio padrão relativo sempre menores que 4 %, enquanto a sensibilidade experimental foi de 0,3 &mu;g (RSD = 5 %). Em relação à linearidade, o coeficiente de correlação assumiu o valor de 0,998 (p<0,0001), para o intervalo de massa analisada de 0,62 a 10 &mu;g de interferon. Essa metodologia permite a aplicação de RP-HPLC como uma ferramenta poderosa para monitoração de níveis de expressão e qualidade do interferon-&alpha;2 durante ou logo após a fermentação. A temperatura ótima de expressão foi avaliada nos intervalos de 30 a 42 °C, em cultivo em erlenmeyer. As produções volumétrica e específica foram maiores para temperaturas iguais ou superiores a 35 °C. Dessa forma, considerando a potencial degradação da proteína recombinante induzida pela temperatura, a temperatura ótima para a expressão de interferon neste processo foi definida como 35 °C. Os maiores valores de produção específica e volumétrica obtidos, em produção em erlenmeyer, foram 1,04 &mu;g/mL/A600 e 3,45 mg/L, respectivamente. Foi padronizado um método de purificação laboratorial, em duas etapas: uma cromatografia de troca iônica, seguida de uma etapa de cromatografia de exclusão molecular. A pureza final e a recuperação em massa foram de, respectivamente, 95,3 % e 66 %. O produto final também foi caracterizado por meio de análise em SDS-PAGE, western blotting, espectrometria de massas, HPLC de exclusão molecular e HPLC em fase reversa.<br>IFN-&alpha;2 is currently utilized in hepatitis B and C, leukemia, multiple myeloma, hairy cell leukemia, melanoma, Kaposi\'s sarcoma, follicular lymphoma, and renal cell carcinoma therapy, with or without other drugs. In this work, a process for E. coli periplasmic interferon-&alpha;2a production and purification utilizing a lambda PL promoter based on constitutive expression was proposed. As a tool for production monitoring, reversedphase high-performance liquid chromatography (RP-HPLC) analysis directly from periplasmic extract was validated. Thus, initially it was described a RP-HPLC methodology for qualitative and quantitative analysis of recombinant human interferon-&alpha;2a and interferon-&alpha;2b. The method has been set up and validated for accuracy, precision, linearity, sensitivity and specificity. A recovery test indicated a bias of less than 1% and intra-day and inter-day quantitative determinations presented relative standard deviations always < 4 %, while experimental sensitivity was 0.3 &mu;g (RSD = 5 %). Regarding to linearity, the coefficient of determination was 0.998 (p<0.0001), for a range of analyzed interferon mass from 0,62 to 10 &mu;g. This rapid methodology allows the application of the RP-HPLC as a powerful tool to monitor the production yield and quality of periplasmic Interferon &alpha;2 right after, or even during the fermentation. The optimum expression temperature was evaluated in flask cultures from 30 to 42 °C. It was observed that the volumetric and specific production were higher for culture temperatures equal or above 35 °C. Thus, considering the potential recombinant protein degradation induced by temperature, 35 °C was well-marked as the optimum temperature for interferon expression. The higher values for specific and volumetric production in culture flasks were 1.04 &mu;g/mL/A600 and 3.45 mg/L respectively. As purification method, it was utilized ionic chromatography followed by size-exclusion chromatography. The final purity and mass recovery was, respectively, 95.3 % and 66 %. The final product was also characterized utilizing SDS-PAGE, western blotting, reversed-phase HPLC, size-exclusion HPLC and mass spectrometry analysis.
APA, Harvard, Vancouver, ISO, and other styles
2

Lima, e. Castro Paula Maria. "Optimisation of CHO cell growth and recombinant interferon-γ production". Thesis, University College London (University of London), 1993. http://discovery.ucl.ac.uk/1317969/.

Full text
Abstract:
The optimisation of recombinant protein production by animal cell cultures is important for the economic feasibility of these processes. Simultaneously with product yield, product authenticity is a crucial aspect to consider as it may per se affect the therapeutic value of such proteins. More defined culture media are being developed, particularly to ensure batch product consistency. A Chinese Hamster Ovary cell line (CHO 320) producing human interferon-γ (IFN-γ), a glycosylated protein, was chosen to investigate the effects of the culture environment on (I) cell growth, (2) product yield and (3) product authenticity. A statistical approach was used to identify important culture components for cell growth and IFN-γ production. When the concentration of the resulting positive variables was initially increased in culture, improvements of approximately 40% in both of these parameters were achieved; the glycosylation of IFN-γ was not affected. The former analysis also indicated that different stimuli were required for growth and production. Fed-batch feeding of glucose and glutamine, components depleted early from culture, did not prolong cell growth or IFN-γ production but the initial glycosylation pattern of IFN-γ was a function of glutamine concentration. Bovine serum albumin (BSA) was shown to have important role(s) in culture and cell growth was not possible in its absence. Pluronic F68, alone or in combination with a lipid mixture or linoleic acid, was able to restore cell growth in low BSA (1 mg/ml) cultures. However, IFN-γ production was significantly reduced and the extent of IFN-γ glycosylation also changed. These effects were related to: (1) BSA concentration, (2) BSA type, and ultimately, (3) lipid composition of the culture. The results reported in this thesis exhibit the necessity to consider the effects of the culture environment not only on cell growth and product yield but also on product authenticity throughout any optimisation process.
APA, Harvard, Vancouver, ISO, and other styles
3

Yeoman, H. "Modulation of the immune recognition of tumours." Thesis, University of Nottingham, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.377451.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Green, Nicola Helen. "The glycosylation of recombinant human interferon-gamma in Chinese hamster ovary cells." Thesis, University of Kent, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.245661.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vaghefi, Negin Gitiban. "The role of innate immunity in protection against respiratory syncytial virus (RSV)." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1138388518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

DELESALLE, PIERRE-HENRI. "Apport de l'interferon alpha recombinant dans le traitement de la leucemie a tricholeucocytes." Lille 2, 1989. http://www.theses.fr/1989LIL2M342.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Argyle, David John. "Cloning sequencing, expression and demonstration of biological activity of feline recombinant interferon-gamma." Thesis, University of Glasgow, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Leal, Rodolfo Assis Oliveira. "Recombinant feline interferon omega therapy in cats naturally infected with Feline Immunodeficiency Virus : clinical, viral and immunological relevance." Doctoral thesis, Universidade de Lisboa. Faculdade de Medicina Veterinária, 2014. http://hdl.handle.net/10400.5/7458.

Full text
Abstract:
Tese de Doutoramento em Ciências Veterinárias Especialidade de Clínica<br>Type-I Interferons are well-known cytokines which among their main functions are key components of the host immune response against viral infections. Due to its immune modulation properties, they are commonly used in the therapeutic approach of various diseases such as retroviral infections. Recombinant feline interferon omega (rFeIFN-ω) is the first interferon licensed for use in veterinary medicine. Although it is commonly administered in retroviral infections, namely in Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) infected cats, few studies reported its clinical benefits and mechanisms of action. This thesis aims to clarify the main properties of the licensed rFeIFN-ω protocol (3 cycles of 5 daily subcutaneous administrations of 1MU/kg beginning on days 0, 14 and 60) in naturally retroviral infected cats living in an animal shelter, evaluating its effect not only on clinical improvement but also on concurrent viral excretion, viremia/proviral load and various immune biomarkers such as acute phase proteins and cytokine profile. Recognizing the non specific and subtle clinical presentation of the majority of FIV-infected cats, this work also presents and evaluates an alternative oral rFeIFN-ω protocol (0.1MU/cat during 90 days) to be used in client-owned FIV-infected cats. Results showed that the licensed rFeIFN-ω protocol induces a significant clinical improvement, with a concurrent reduction of opportunistic viral infections and an increase on acute phase proteins (APP) profile. The alternative protocol also revealed an important clinical improvement but without significant changes on opportunistic viral infections (which were of low level in the tested group) or on APP profile. In both protocols, no changes were remarked on viremia neither on T-helper 1/T-helper 2 cytokine profiles meaning that this compound may lack an anti-viral activity for retroviruses in vivo and do not act on the acquired immune response of FIV-positive cats. However, there was a significant reduction of the interleukin-6 plasma levels (pro-inflammatory cytokine) in cats treated with the licensed protocol and a decrease on its mRNA expression in cats treated orally. This shows that rFeIFN-ω can have anti-inflammatory properties, which are more evident in the higher doses of the licensed protocol. More than contributing for a better knowledge of rFeIFN-ω, this thesis explores its immune modulation properties and validates a new oral protocol which can be included on future FIV-guidelines.<br>Resumo - A terapêutica com interferão ómega felino em gatos naturalmente infectados com o vírus da imunodeficiência felina: relevância clinica, virológica e imunitária - Os interferões do tipo I são citoquinas chave do sistema imunitário. Devido às suas propriedades imunomoduladoras, são um recurso terapêutico frequente em diferentes doenças como as infecções retrovirais. O interferão ómega felino (rFeIFN-ω) é o primeiro interferão licenciado para medicina veterinária. Apesar do seu uso no tratamento de infeções retrovirais como o vírus da imunodeficiência felina (FIV) e o vírus da leucemia felina (FeLV), são poucos os estudos que fundamentam o seu benefício clinico. Esta tese visa clarificar as propriedades terapêuticas e imunomoduladoras do protocolo licenciado de rFeIFN-ω (3 ciclos de 5 administrações subcutâneas de 1MU/kg uma vez ao dia a iniciar aos dias 0, 14 e 60) em gatos naturalmente infectados por retrovírus e residentes em gatil. Em detalhe, este trabalho avalia o efeito deste fármaco na melhoria clinica, na excreção de vírus concomitantes, na virémia/provirus e na variação de diferentes marcadores imunitários como proteínas de fase aguda e perfil de citoquinas. Esta tese contempla ainda o desenvolvimento de um protocolo terapêutico alternativo baseado na administração oral de rFeIFN-ω (0.1MU/gato durante 90 dias consecutivos) para uso em gatos FIV-positivos domésticos, os quais apresentam geralmente um quadro clinico subtil e pouco específico. Os resultados revelaram que o protocolo licenciado induz uma melhoria clinica significativa com redução concomitante das infecções oportunistas e um aumento do perfil de proteínas de fase aguda (APP). O protocolo alternativo revelou-se eficaz na melhoria clinica dos animais tratados, apesar de não induzir alterações significativas do perfil de APPs nem das infecções concomitantes (residuais no grupo de estudo). Ambos os protocolos não induziram alterações na virémia nem no perfil de citoquinas participantes nas respostas T-helper 1 ou T-helper 2 o que sugere que este composto não apresenta propriedades anti-virais nem actua na imunidade adquirida de gatos FIV positivos. Verificou-se contudo um decréscimo dos niveis plasmáticos de Interleucina-6 (citoquina pro-inflamatória) em gatos tratados com o protocolo subcutâneo e uma redução da sua expressão (mRNA) em gatos tratados por vira oral. Tal demonstra que o rFeIFN-ω apresenta propriedades anti-inflamatórias, as quais são mais evidentes aquando do tratamento com o protocolo licenciado. Mais que uma contribuição para um melhor conhecimento do rFeIFN-ω, esta tese explora as suas propriedades imunomoduladoras e valida um novo protocolo oral, o qual poderá ser incluído em futuras guidelines para o tratamento de gatos FIV-positivos.<br>Trabalho financiado também pelo Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA) da Faculdade de Medicina Veterinária, Universidade de Lisboa e Virbac (Centro de Custos phD_Virbac).
APA, Harvard, Vancouver, ISO, and other styles
9

Wingrove, Callum Scott. "Post-translational modifications of recombinant human interferon-#gamma# in the CHO 320 cell line." Thesis, University of Kent, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.357687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

CARDON, BERNARD. "Traitement du sarcome de kaposi au cours du sida par l'interferon alpha 2 a recombinant humain : a propos de 102 cas." Lille 2, 1989. http://www.theses.fr/1989LIL2M051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Recombinant interferon"

1

Lindenmann, J., and W. D. Schleuning, eds. Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

B, Whittet D. C., ed. Planetary and interstellar processes relevant to the origins of life. Kluwer Academic Publishers, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Huub, Schellekens, ed. Antibodies in cytokines: The concerted action on the antigenicity of rDNA derived pharmaceuticals. Kluwer Academic, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United Nations. Economic Commission for Latin America and the Caribbean., ed. Biotecnología e industria farmaceútica: Desarrollo y producción de Interferon natural y recombinante en un laboratorio argentino. CEPAL Buenos Aires, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schleuning, W. D., and J. Lindenmann. Interferon: The Dawn of Recombinant Protein Drugs. Springer London, Limited, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lindenmann, J., and W. D. Schleuning. Interferon: The Dawn of Recombinant Protein Drugs. Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bollon, Arthur P. Recombinant DNA Products: Insulin, Interferon and Growth Hormone. Crc Pr I Llc, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bollon, Arthur P. Recombinant DNA Products: Insulin, Interferon and Growth Hormone. Taylor & Francis Group, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bollon, Arthur P. Recombinant DNA Products: Insulin, Interferon and Growth Hormone. Taylor & Francis Group, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bollon, Arthur P. Recombinant DNA Products: Insulin, Interferon and Growth Hormone. Taylor & Francis Group, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Recombinant interferon"

1

Weissmann, Charles. "Recombinant interferon - the 20th anniversary." In Recombinant Protein Drugs. Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8346-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nagabhushan, T. L., and P. J. Leibowitz. "Recombinant DNA Technology and Characterization of Recombinant Alpha-2 Interferon." In Interferon Alpha-2: Pre-Clinical and Clinical Evaluation. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2579-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Finter, N. B. "Is There Life Without Interferon?" In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lindenmann, J., and W. D. Schleuning. "Interferon: The Dawn of Recombinant Protein Drugs." In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

van Furth, R., J. A. M. Langermans, and M. F. Geertsma. "Activation of Phagocytes by Recombinant Interferon-γ." In Immunotherapeutic Prospects of Infectious Diseases. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76120-1_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Playfair, J. H. L., A. W. Heath, and J. B. De Souza. "Recombinant Gamma Interferon as an Immunological Adjuvant." In Immunological Adjuvants and Vaccines. Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fitzgerald-Bocarsly, P. "Interferon-α: From Pass Interference to Cytokine Networking." In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pieters, T. "What Constitutes Therapeutic Success? The Interferons (1978–1998)." In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Löwy, I. "The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy." In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kawade, Y. "A Biosemiotic View of Interferon: Toward a Biology of Really Living Organisms." In Interferon: The Dawn of Recombinant Protein Drugs. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-662-03787-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Recombinant interferon"

1

JIN, TING, YI-XIN GUAN, HAI-XUE PAN, SHAN-JING YAO, and MAN-GI CHO. "PREPARATION AND REFOLDING OF RECOMBINANT HUMAN INTERFERON-GAMMA INCLUSION BODIES." In Proceedings of the 4th International Conference. WORLD SCIENTIFIC, 2004. http://dx.doi.org/10.1142/9789812702623_0078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Goloshchapova, E. O., A. S. Minero, O. B. Runova, and O. B. Ustinnikova. "STRUCTURE IDENTITY OF RECOMBINANT INTERFERON BETA-1b MOLECULE: VERIFICATION METHOD DEVELOPMENT." In Molecular Diagnostics and Biosafety. Federal Budget Institute of Science 'Central Research Institute for Epidemiology', 2020. http://dx.doi.org/10.36233/978-5-9900432-9-9-207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

GUAN, YI-XIN, ZHENG-ZHENG FEI, and SHAN-JING YAO. "RENATURATION OF RECOMBINANT HUMAN INTERFERON GAMMA IN THE PRESENCE OF MINICHAPERONE GROEL 191-345." In Proceedings of the 4th International Conference. WORLD SCIENTIFIC, 2004. http://dx.doi.org/10.1142/9789812702623_0134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gorinsky, Vitaly Ivanovich, Vladimir Vasilyevich Salautin, Nikolay Alexandrovich Pudovkin, and Svetlana Evgenievna Salautina. "ADJUVANT COMBINED SYSTEMIC IMMUNO-CHEMOTHERAPY WITH RECOMBINANT INTERFERON OMEGA AND DOXORUBICIN FIBROSARCOMA INJECTION SITES IN CATS." In Themed collection of papers from Foreign international scientific conference «Joint innovation - joint development». Part 2. by HNRI «National development» in cooperation with PS of UA. October 2023. - Harbin (China). Crossref, 2024. http://dx.doi.org/10.37539/231024.2023.45.52.029.

Full text
Abstract:
This article presents the results of studies aimed at evaluation of the efficacy of combined systemic immunochemotherapy of injection site feline fibrosarcoma in combination with surgical resection of the tumor. The recorded mean duration of the relapse-free period in the combined immunochemotherapy group was 275 days (± 50.9); in the chemotherapy group, it was 178 days (± 26.7).
APA, Harvard, Vancouver, ISO, and other styles
5

Vavilova, Vera, Aleksandr Vavilov, Anastasia Cherkaeva та Irina Nechaeva. "P536 Modern opportunities for vaccination PCV13 in children suffering chronical inflammation nasopharyngeal diseases using recombinant α2b-interferon". У Faculty of Paediatrics of the Royal College of Physicians of Ireland, 9th Europaediatrics Congress, 13–15 June, Dublin, Ireland 2019. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-epa.870.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pykhtina, Maria, Vladimir Romanov, Anastasiya Kotlyarova, et al. "Engineering and characterization of a recombinant human interferon alpha-2b fused with apolipoprotein A-I possessing prolonged action." In 6th International Electronic Conference on Medicinal Chemistry. MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kikhtenko, Nikolai, Tatyana Ilyicheva, Larisa Oleynik, Anzhella Fursova, and Pavel Madonov. "Investigation of antiviral activity of recombinant human interferon lambda-1 in the model of adenovirus infection of the eye." In 2022 Ural-Siberian Conference on Computational Technologies in Cognitive Science, Genomics and Biomedicine (CSGB). IEEE, 2022. http://dx.doi.org/10.1109/csgb56354.2022.9865362.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bing Han, Yulai Zhou, Minghua Duan, et al. "Preparation of a novel formulaton of recombinant human interferon α-2b suppository and its studies on quality control and stability." In 2011 International Conference on Remote Sensing, Environment and Transportation Engineering (RSETE). IEEE, 2011. http://dx.doi.org/10.1109/rsete.2011.5964339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Okolysheva, Nadezhda, Lidiia Kisteneva, Valentina Malinovskaya, Svyatoslav Cheshik, Elena Ruzhitskaya та Alexey Semenov. "Effect of recombinant α2-β-interferon therapy on virologic and immunologic characteristics by children at early age with acute respiratory viral infections". У Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.oa1989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Choo, Su Pin, Wai Meng Tai, Maria Macapagal, et al. "Abstract A027: A phase I open-label, non-randomized study of recombinant compound interferon (rSIFN-co) in patients with advanced solid tumors." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-a027.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Recombinant interferon"

1

Lillehoj, Hyun, Dan Heller, and Mark Jenkins. Cellular and molecular identification of Eimeria Acervulina Merozoite Antigens eliciting protective immunity. United States Department of Agriculture, 1992. http://dx.doi.org/10.32747/1992.7561056.bard.

Full text
Abstract:
Coccidiosis, ubiquitous diseases of poultry, seriously impair the growth and feed utilization of livestock and poultry. Coccidiosis causes over $600 million annual losses world-wide and no vaccine is currently available. The goal of this study was to investigate the cellular and molecular mechanisms controlling protective immune responses to coccidia parasites in order to develop immunological control strategy against coccidiosis. The major findings of this study were: 1) cell-mediated immunity plays a major role in protection against coccidiosis, 2) when different genetic lines showing different levels of disease susceptibility were compared, higher T-cell response was seen in the strains of chickens showing higher disease resistance, 3) early interferon secretion was observed in more coccidia-resistant chicken strains, 4) both sporozoite and merozoite antigens were able to induce interferon production, and 5) chicken monoclonal antibodies which detect immunogenic coccidia proteins have been developed. This study provided a good background work for future studies toward the development of recombinant coccidial vaccine. Availability of chicken monoclonal antibodies which detect immunogenic coccidia proteins will enhance our ability to identify potential coccidial vaccine antigens.
APA, Harvard, Vancouver, ISO, and other styles
2

Davidson, Irit, Hsing-Jien Kung, and Richard L. Witter. Molecular Interactions between Herpes and Retroviruses in Dually Infected Chickens and Turkeys. United States Department of Agriculture, 2002. http://dx.doi.org/10.32747/2002.7575275.bard.

Full text
Abstract:
Tumors in commercial poultry are caused mainly by infection with avian herpes and retroviruses, the herpesvirus Marek's disease virus (MDV) and the retroviruses, reticuloendotheliosis (REV), lymphoid leukosis, subgroups A-I and J (ALV and ALV-J) in chickens, or Iymphoprolipherative disease (LPDV) in turkeys. Infection with one virus aggravates the clinical outcome of birds that are already infected by another oncogenic virus. As these viruses do not interfere for infection, MDV and one or more retroviruses can infect the same flock, the same bird and the same cell. While infecting the same cell, herpes and retroviruses might interact in at least three ways: a) Integration of retrovirus genomes, or genomic fragments (mainly the LTR) into MDV;b) alteration of LTR-driven expression of retroviral genes by MDV immediate- early genes, and c) by herpesvirus induced cellular transcriptional factors. The first type of molecular interaction have been demonstrated to happen efficiently in vitro by Dr. Kung, in cases multiple infection of cell cultures with MDV and REV or MDV and ALV. Moreover, Dr. Witter showed that an in vitro-created recombinant, RM1, had altered in vitro replication and in vivo biological properties. A more comprehensive characterization of RM1 was carried out in the present project. We sought to highlight whether events of such integrations occur also in the bird, in vivo. For that, we had first to determine the prevalence of dually-infected individual birds in commercial flocks, as no systematic survey has been yet reported. Surprisingly, about 25% of the commercial flocks infected with avian oncogenic viruses had a multiple virus infection and 5% of the total samples ana lysed had multiple virus sequences. Then, we aimed to evaluate and characterize biologically and molecularly the resulting recombinants, if formed, and to analyse the factors that affect these events (virus strains, type and age of birds and time interval between the infection with both viruses). The perception of retrovirus insertions into herpesviruses in vivo is not banal, as the in vivo and in vitro systems differ in the viral-target cells, lymphocytes or fibroblasts, in the MDV-replicative type, transforming or productive, and the immune system presence. We realized that previous methods employed to study in vitro created recombinant viruses were not adequate for the study of samples taken directly from the bird. Therefore, the Hot Spot-combined PCR was developed based on the molecularly known RM1 virus. Also, the PFGE that was used for tissue cultured-MDV separation was inefficient for separating MDV from organs, but useful with feather tips as a source of bird original MDV. Much attention was dedicated now to feathers, because if a recombinant virus would be formed in vivo, its biological significance would be evident by horizontal dissemination through the feathers. Major findings were: a) not only in vitro, but also in vivo MDV and retrovirus co-infections lead to LTR integrations into MDV. That was shown by the detection of chimeric molecules. These appeared in low quantities and as quasispecies, thus interfering with sequence analysis of cloned gel-purified chimeric molecules. Mainly inserts were located in the repeat long MDV fragments. In field birds chimeric molecules were detected at a lower frequency (2.5%) than in experimentally infected birds (30-50%). These could be transmitted experimentally to another birds by inoculation with chimeric molecules containing blood. Several types of chimeric molecules were formed, and same types were detected in birds infected by a second round. To reproduce viral integrations, in vivo infection trials were done with field inoculate that contained both viruses, but the chimeric molecule yield was undetectable.
APA, Harvard, Vancouver, ISO, and other styles
3

Mawassi, Munir, and Valerian Dolja. Role of RNA Silencing Suppression in the Pathogenicity and Host Specificity of the Grapevine Virus A. United States Department of Agriculture, 2010. http://dx.doi.org/10.32747/2010.7592114.bard.

Full text
Abstract:
RNA silencing is a defense mechanism that functions against virus infection and involves sequence-specific degradation of viral RNA. Diverse RNA and DNA viruses of plants encode RNA silencing suppressors (RSSs), which, in addition to their role in viral counterdefense, were implicated in the efficient accumulation of viral RNAs, virus transport, pathogenesis, and determination of the virus host range. Despite rapidly growing understanding of the mechanisms of RNA silencing suppression, systematic analysis of the roles played by diverse RSSs in virus biology and pathology is yet to be completed. Our research was aimed at conducting such analysis for two grapevine viruses, Grapevine virus A (GVA) and Grapevine leafroll-associated virus-2 (GLRaV- 2). Our major achievements on the previous cycle of BARD funding are as follows. 1. GVA and GLRaV-2 were engineered into efficient gene expression and silencing vectors for grapevine. The efficient techniques for grapevine infection resulting in systemic expression or silencing of the recombinant genes were developed. Therefore, GVA and GLRaV-2 were rendered into powerful tools of grapevine virology and functional genomics. 2. The GVA and GLRaV-2 RSSs, p10 and p24, respectively, were identified, and their roles in viral pathogenesis were determined. In particular, we found that p10 functions in suppression and pathogenesis are genetically separable. 3. We revealed that p10 is a self-interactive protein that is targeted to the nucleus. In contrast, p24 mechanism involves binding small interfering RNAs in the cytoplasm. We have also demonstrated that p10 is relatively weak, whereas p24 is extremely strong enhancer of the viral agroinfection. 4. We found that, in addition to the dedicated RSSs, GVA and GLRaV-2 counterdefenses involve ORF1 product and leader proteases, respectively. 5. We have teamed up with Dr. Koonin and Dr. Falnes groups to study the evolution and function of the AlkB domain presents in GVA and many other plant viruses. It was demonstrated that viral AlkBs are RNA-specific demethylases thus providing critical support for the biological relevance of the novel process of AlkB-mediated RNA repair.
APA, Harvard, Vancouver, ISO, and other styles
4

Dolja, Valerian V., Amit Gal-On, and Victor Gaba. Suppression of Potyvirus Infection by a Closterovirus Protein. United States Department of Agriculture, 2002. http://dx.doi.org/10.32747/2002.7580682.bard.

Full text
Abstract:
The plant virus family Polyviridae is the largest and most destructive of all plant viruses. Despite the continuous effort to develop resistant plant varieties, there is a desperate need for novel approaches conferring wide-range potyvirus resistance. Based on experiments with the tobacco etch potyvirus (TEV)-derived gene expression vector, we suggested approach for screening of the candidate resistance genes. This approach relies on insertion of the genes into a virus vector and evaluation of the phenotypes of the resulting recombinant viruses. The genes which suppress infection by the recombinant virus are selected as candidates for engineering transgenic resistance. Our analysis of the TEV variants expressing proteins of the beet yellows closterovirus (BYV) revealed that one of those, the leader proteinase (L-Pro), strongly and specifically interfered with the hybrid TEV infection. Since closterovirus L-Pro is evolutionary related to potyviral helper component-proteinase (HC-Pro), we suggested that the L-Pro interfered with HC-Pro function via a trans-dominant inhibitory effect. Based on these findings, we proposed to test two major hypotheses. First, we suggested that L-Pro-mediated suppression of potyvirus infection is a general phenomenon effective against a range of potyviruses. The second hypothesis stated that the suppression effect can be reproduced in transgenic plants expressing L-Pro, and can be utilized for generation of resistance to potyviruses. In accord with these hypotheses, we developed two original objectives of our proposal: A) to determine the range of the closterovirus-derived suppression of potyviral infection, and B) to try and utilize the L-Pro-mediated suppression for the development of transgenic resistance to potyviruses. In the first phase of the project, we have developed all major tools and technologies required for successful completion of the proposed research. These included TEV and ZYMV vectors engineered to express several closteroviral L-Pro variants, and generation of the large collection of transgenic plants. To our satisfaction, characterization of the infection phenotypes exhibited by chimeric TEV and ZYMV variants confirmed our first hypothesis. For instance, similar to TEV-L- Pro(BYV) chimera, ZYMV-L-Pro(LIYV) chimera was debilitated in its systemic spread. In contrast, ZYMV-GUS chimera (positive control) was competent in establishing vigorous systemic infection. These and other results with chimeric viruses indicated that several closteroviral proteinases inhibit long-distance movement of the potyviruses upon co-expression in infected plants. In order to complete the second objective, we have generated ~90 tobacco lines transformed with closteroviral L-Pro variants, as well as ~100 lines transformed with BYV Hsp70-homolog (Hsp70h; a negative control). The presence and expression of the trans gene in each line was initially confirmed using RT-PCR and RNA preparations isolated from plants. However, since detection of the trans gene-specific RNA can not guarantee production of the corresponding protein, we have also generated L-Pro- and Hsp70h-specific antisera using corresponding synthetic peptides. These antisera allowed us to confirm that the transgenic plant lines produced detectable, although highly variable levels of the closterovirus antigens. In a final phase of the project, we tested susceptibility of the transgenic lines to TEV infection. To this end, we determined that the minimal dilution of the TEV inoculum that is still capable of infecting 100% of nontransgenic plants was 1:20, and used 10 plants per line (in total, ~2,000 plants). Unfortunately, none of the lines exhibited statistically significant reduction in susceptibility. Although discouraging, this outcome prompted us to expand our experimental plan and conduct additional experiments. Our aim was to test if closteroviral proteinases are capable of functioning in trans. We have developed agroinfection protocol for BYV, and tested if co- expression of the L-Pro is capable of rescuing corresponding null-mutant. The clear-cut, negative results of these experiments demonstrated that L-Pro acts only in cis, thus explaining the lack of resistance in our transgenic plants. We have also characterized a collection of the L-Pro alanine- scanning mutants and found direct genetic evidence of the requirement for L-Pro in virus systemic spread. To conclude, our research supported by BARD confirmed one but not another of our original hypotheses. Moreover, it provided an important insight into functional specialization of the viral proteinases and generated set of tools and data with which we will be able to address the molecular mechanisms by which these proteins provide a variety of critical functions during virus life cycle.
APA, Harvard, Vancouver, ISO, and other styles
5

Bercovier, Herve, Raul Barletta, and Shlomo Sela. Characterization and Immunogenicity of Mycobacterium paratuberculosis Secreted and Cellular Proteins. United States Department of Agriculture, 1996. http://dx.doi.org/10.32747/1996.7573078.bard.

Full text
Abstract:
Our long-term goal is to develop an efficient acellular vaccine against paratuberculosis based on protein antigen(s). A prerequisite to achieve this goal is to analyze and characterize Mycobacterium paratuberculosis (Mpt) secreted and cellular proteins eliciting a protective immune response. In the context of this general objective, we proposed to identify, clone, produce, and characterize: the Mpt 85B antigen and other Mpt immunoreactive secreted proteins, the Mpt L7/L12 ribosomal protein and other immunoreactive cellular proteins, Mpt protein determinants involved in invasion of epithelial cells, and Mpt protein antigens specifically expressed in macrophages. Paratuberculosis is still a very serious problem in Israel and in the USA. In the USA, a recent survey evaluated that 21.6% of the dairy herd were infected with Mpt resulting in 200-250 million dollars in annual losses. Very little is known on the virulence factors and on protective antigens of Mpt. At present, the only means of controlling this disease are culling or vaccination. The current vaccines do not allow a clear differentiation between infected and vaccinated animals. Our long-term goal is to develop an efficient acellular paratuberculosis vaccine based on Mpt protein antigen(s) compatible with diagnostic tests. To achieve this goal it is necessary to analyze and characterize secreted and cellular proteins candidate for such a vaccine. Representative Mpt libraries (shuttle plasmid and phage) were constructed and used to study Mpt genes and gene products described below and will be made available to other research groups. In addition, two approaches were performed which did not yield the expected results. Mav or Mpt DNA genes that confer upon Msg or E. coli the ability to invade and/or survive within HEp-2 cells were not identified. Likewise, we were unable to characterize the 34-39 kDa induced secreted proteins induced by stress factors due to technical difficulties inherent to the complexity of the media needed to support substantial M. pt growth. We identified, isolated, sequenced five Mpt proteins and expressed four of them as recombinant proteins that allowed the study of their immunological properties in sensitized mice. The AphC protein, found to be up regulated by low iron environment, and the SOD protein are both involved in protecting mycobacteria against damage and killing by reactive oxygen (Sod) and nitrogen (AhpC) intermediates, the main bactericidal mechanisms of phagocytic cells. SOD and L7/L12 ribosomal proteins are structural proteins constitutively expressed. 85B and CFP20 are both secreted proteins. SOD, L7/L12, 85B and CFP20 were shown to induce a Th1 response in immunized mice whereas AphC was shown by others to have a similar activity. These proteins did not interfere with the DTH reaction of naturally infected cows. Cellular immunity provides protection in mycobacterial infections, therefore molecules inducing cellular immunity and preferentially a Th1 pathway will be the best candidate for the development of an acellular vaccine. The proteins characterized in this grant that induce a cell-mediated immunity and seem compatible with diagnostic tests, are good candidates for the construction of a future acellular vaccine.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Recombinant interferon' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography